via News-Medical.Net
Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
Learn more: Mayo Clinic researchers identify potential new therapy for liver diseases
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- Amid pandemic three infants get life-saving liver transplantson August 10, 2020 at 8:35 am
The three had the same rare disease, biliary atresia ... In the condition, bile ducts that drain bile from the liver to the intestine are not properly formed. With progressive jaundice and liver ...
- Heart Disease Therapeutics Could Arise from Newly Discovered Mutationon August 10, 2020 at 5:00 am
Research points to potential to reduce triglyceride levels without the risk of unpleasant and serious side effects in the intestines and liver.
- Abnormal liver tests associated with poorer COVID-19 outcomeson August 9, 2020 at 4:54 am
Researchers at the Yale Liver Center found that patients with COVID-19 presented with abnormal liver tests at much higher rates than suggested by earlier studies.
- Strong link found between abnormal liver tests and poor COVID-19 outcomeson August 8, 2020 at 3:17 pm
Researchers at the Yale Liver Center found that patients with COVID-19 presented with abnormal liver tests at much higher rates than suggested by earlier ...
- Patients at high risk for coronavirus should watch out for this common liver condition, doctor warnson August 7, 2020 at 11:44 am
Certain medical conditions raise the risk for more severe COVID-19 disease, and one doctor is raising awareness of a widespread liver condition that may be unfamiliar to some.
- HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver canceron August 7, 2020 at 2:38 am
The molecular determinants of differential responses of different cancer cells to methionine restriction are poorly understood. Here the authors show that hepatocyte nuclear factor 4α regulates sulfur ...
- Study shows liver injury is common and prognostic in COVID-19 patientson August 6, 2020 at 5:25 am
Researchers from the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) have recently conducted a study to investigate the impact of liver injury on clinical outcomes in COVID-19 ...
- Scientists explore mechanisms involved in the development of liver diseaseon August 5, 2020 at 11:06 pm
Metabolic fatty liver disease, known as non-alcoholic fatty liver disease, is one of the most common causes of liver disease in Western countries and covers a spectrum of disorders.
- Osteopontin, a protein not always as bad as it is made out to beon August 5, 2020 at 8:15 am
Metabolic fatty liver disease, known as non-alcoholic fatty liver disease, is one of the most common causes of liver disease in Western countries and covers a spectrum of disorders. It is strongly ...
- Non Alcoholic Fatty Liver Disease Solution by Julissa Clay (Blue Heron)on August 5, 2020 at 2:00 am
The Non Alcoholic Fatty Liver Disease Solution is a guide by Blue Heron Health News’ Julissa Clay that shows consumers three different changes they need to make in their lives to eliminate their ...
via Bing News
